Literature DB >> 19328224

Upregulation of beta-catenin expression in down syndrome model Ts65Dn mouse brain.

N Ramakrishna1, H C Meeker, S Li, W T Brown, R Rao, A El Idrissi.   

Abstract

Trisomy of human chromosome 21 (Hsa 21) causes the pathological characteristics of Down syndrome (DS). Little is known about the mechanisms by which trisomy 21 affects the expression of genes on other chromosomes. Using a mouse model of DS, the Ts65Dn mouse, we have performed mRNA and protein measurements to identify genes on chromosomes not syntenic with Hsa 21 whose expression is affected by the presence of three copies of genes between loci Mrpl39 and Znf295 on mouse chromosome 16 (Mmu 16). We report the upregulation of beta-catenin, located on mouse chromosome 9 (Mmu 9) in Ts65Dn brain. Using immunocytochemistry on Ts65Dn and control mouse brain tissue, we observed a striking increase in beta-catenin expression specifically in the endothelial cells lining the cerebral blood vessels of the Ts65Dn mice. Since beta-catenin is involved in cell-cell adhesion, upregulation of this protein in DS may alter adherens protein interactions that are involved in the normal functions of endothelial cells. Elevated beta-catenin might be responsible for altered endothelial cell function/s leading to the impairment of brachial flow velocity observed in DS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19328224     DOI: 10.1016/j.neuroscience.2009.03.049

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  2 in total

Review 1.  Molecular and cellular alterations in Down syndrome: toward the identification of targets for therapeutics.

Authors:  Nicole Créau
Journal:  Neural Plast       Date:  2012-07-12       Impact factor: 3.599

2.  Down syndrome and the molecular pathogenesis resulting from trisomy of human chromosome 21.

Authors:  Aarti Ruparelia; Frances Wiseman; Olivia Sheppard; Victor L J Tybulewicz; Elizabeth M C Fisher
Journal:  J Biomed Res       Date:  2010-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.